Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded natural killer cell infusion for acute myeloid leukemia
RBR-8qq5h9Phase 2Not yet recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Jan 2020
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of expanded natural killer cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Hospital Israelita Albert Einstein. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on RBR-8qq5h9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8qq5h9.